SkinBioTherapeutics (LSE:SBTX) Capex-to-Revenue : 0.71 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is SkinBioTherapeutics Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

SkinBioTherapeutics's Capital Expenditure for the six months ended in Dec. 2023 was £-0.08 Mil. Its Revenue for the six months ended in Dec. 2023 was £0.11 Mil.

Hence, SkinBioTherapeutics's Capex-to-Revenue for the six months ended in Dec. 2023 was 0.71.

SkinBioTherapeutics Capex-to-Revenue Historical Data

The historical data trend for SkinBioTherapeutics's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SkinBioTherapeutics Capex-to-Revenue Chart

SkinBioTherapeutics Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Capex-to-Revenue

Get a 7-Day Free Trial

1.29

1.25

SkinBioTherapeutics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Capex-to-Revenue	Get a 7-Day Free Trial										1.91	1.04	0.35	2.51	0.71

Competitive Comparison of SkinBioTherapeutics's Capex-to-Revenue

For the Biotechnology subindustry, SkinBioTherapeutics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SkinBioTherapeutics's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SkinBioTherapeutics's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where SkinBioTherapeutics's Capex-to-Revenue falls into.

SkinBioTherapeutics Capex-to-Revenue Calculation

SkinBioTherapeutics's Capex-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.165)	/	0.132
	=	1.25

SkinBioTherapeutics's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.076)	/	0.107
	=	0.71

SkinBioTherapeutics (LSE:SBTX) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

SkinBioTherapeutics Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of SkinBioTherapeutics's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

SkinBioTherapeutics (LSE:SBTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SkinBioTherapeutics PLC (LSE:SBTX) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bath Lane, The Core, Newcastle Helix, Newcastle upon Tyne, GBR, NE4 5TF

Website

https://www.skinbiotherapeutics.com

SkinBioTherapeutics PLC is a life science company focused on skin health. It is focused on the development of technology to protect, manage, and restore skin utilizing proteins found in the human microbiota. It is targeting three specific skin healthcare sectors; cosmetics, infection control, and eczema.